Geisinger Heart Institute, Wilkes-Barre, Pennsylvania.
Geisinger Heart Institute, Wilkes-Barre, Pennsylvania.
Heart Rhythm. 2024 Oct;21(10):1953-1961. doi: 10.1016/j.hrthm.2024.04.054. Epub 2024 May 17.
Conduction system pacing (CSP) by His bundle pacing or left bundle branch area pacing (LBBAP) is incorporated into Heart Rhythm Society guidelines for the management of bradycardia and cardiac resynchronization therapy. Despite increasing adoption with both lumenless leads and stylet-driven leads, concerns regarding the feasibility and safety of the extraction of CSP leads remain.
The aim of the study was to report on the safety, feasibility, and clinical outcomes of the extraction of CSP leads.
Patients undergoing the extraction of CSP leads from 10 international centers were enrolled in this retrospective study. Data regarding indications, lead location, lead type, extraction tools, procedural success, complications, and reimplantation in the conduction system were collected.
Overall, 341 patients (age 69 ± 15 years; female 117 (34%); cardiomyopathy 157 (46%); lead dwell time 22 ± 26 months) underwent the extraction of 224 His bundle pacing and 117 LBBAP leads (lumenless leads 321; stylet-driven leads 20). Complete procedural success was achieved in 338 (99%), while clinical success was 100% with retained distal fragments in 3 patients (1%). Among patients with a lead dwell time of >6 months (6-193 months; n = 226), manual extraction was successful in 198 (87%), mechanical tools in 22 (10%), and laser in 6 (3%). Femoral tools were necessary in 3 patients. Minor complications occurred in 7 patients (2.1%). Reimplantation in the conduction system was successful in 233 of 244 patients attempted (95%).
The overall success rates of the extraction of CSP leads were very high (although the LBBAP lead dwell time was <3 years), with a low need for extraction tools and minimal complication. Reimplantation in the conduction system is feasible and safe.
希氏束起搏或左束支区域起搏(LBBAP)的心脏传导系统起搏(CSP)已被纳入心脏节律协会关于心动过缓和心脏再同步治疗管理的指南。尽管随着无腔导丝和导丝驱动导丝的应用越来越多,但对于 CSP 导丝提取的可行性和安全性仍存在担忧。
本研究旨在报告 CSP 导丝提取的安全性、可行性和临床结果。
从 10 个国际中心招募了接受 CSP 导丝提取的患者进行这项回顾性研究。收集了关于适应证、导丝位置、导丝类型、提取工具、程序成功、并发症和在传导系统中重新植入的的数据。
总体而言,341 例患者(年龄 69±15 岁;女性 117 例(34%);心肌病 157 例(46%);导丝留置时间 22±26 个月)接受了 224 例希氏束起搏和 117 例 LBBAP 导丝(无腔导丝 321 例;导丝驱动导丝 20 例)的提取。338 例(99%)达到完全程序成功,3 例(1%)因保留了远端碎片而达到临床成功。在导丝留置时间>6 个月(6-193 个月;n=226)的患者中,手动提取成功 198 例(87%),机械工具提取成功 22 例(10%),激光提取成功 6 例(3%)。3 例患者需要使用股部工具。7 例患者(2.1%)出现轻微并发症。233 例(95%)尝试重新植入传导系统的患者获得成功。
CSP 导丝提取的总体成功率非常高(尽管 LBBAP 导丝留置时间<3 年),需要提取工具的比例低,并发症很少。在传导系统中重新植入是可行和安全的。